A study conducted in the Netherlands analyzed nearly 1,400 GI cancer patients and found a subgroup of patients who took aspirin post-diagnosis had a higher survival rate than patients who did not, according to a Medscape report.
Patients in the group had various GI cancers including:
• Colon cancer: 48 percent
• Rectal cancer: 42.8 percent
• Esophageal cancer: 10.2 percent
The subgroup of patients who took aspirin had a five-year survival rate of 75 percent, while the patients who did not take aspirin had a five-year survival rate of 40 percent.